CentralCharts: Supercharge your portfolio with groundbreaking tools.

Purchase of own shares LONDON, UK / ACCESSWIRE / May 8, 2024 / The Company announces that on 07 May 2024 it purchased the following number of its ordinary shares of 20 340/399 pence each through Goldman Sachs International (" GSI ") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the " Purchase "). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced...

The Nomination Committee of MGI has resolved to propose re-election of Tobias M. Weitzel as chair of the Board of Directors and re-election of Elizabeth Para, Franca Ruhwedel, Johan Roslund and Remco Westermann as board members. The Nomination Committee also proposes election of Greg Coleman and Peter Huijboom as new board members (conditional on the annual general meeting resolving to increase the maximum number of board members). STOCKHOLM, SWEDEN / ACCESSWIRE / May 8, 2024 / MGI - Media and...

Autohome Inc. Announces 2024 Q1 Earnings: Record Strong Growth in NEV Business and Echo with "Trade-in for new" Policy PR Newswire HONG KONG, May 8, 2024 HONG KONG , May 8, 2024 /PRNewswire/ -- Autohome Inc. (NYSE: ATHM; HKEX: 2518) ("Autohome" or the "Company"), the leading online destination for automobile consumers in China , today announced its first quarter financial results for 2024. Total revenues reached RMB1.61 billion , growing by 4.9% year-over-year. Revenues from the online...

FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming Guggenheim Healthcare Talks Radiopharmaceuticals Day being held on May 13, 2024 in New York City. Details...

Strong across-the-board year-over-year Q1’24 financial performance driven by yield expansion, transaction growth, unit cost reduction and operating expense discipline Q1’24 operating income loss of $(4.1) million more than halved versus a loss of $(17.1) million in the comparable year-ago period Q1’24 adjusted EBITDA up sharply to $17.7 million vs. $0.4 million in the comparable year-ago period Sustaining a strong balance sheet with cash and marketable securities of $443.6 million to...

Insurance Flows and Castlelake Add $75 Billion of AUM Since Quarter End $106 Billion of Dry Powder Available to Invest BROOKFIELD, NEWS, May 08, 2024 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) today announced financial results for the quarter ended March 31, 2024. Connor Teskey, President of Brookfield Asset Management stated, “We are off to a strong start in 2024 and are seeing accelerating momentum across our business as transaction activity picks up. We...

COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025 Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD) Michael Gold to join Compass as Head of R&D Compass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May...